InvestorNewsBreaks - Oragenics Inc. (NYSE American: OGEN) Secures U.S. Manufacturing Partner Ahead of Phase IIb Trials for Concussion Drug

Stock Information for Oragenics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Oragenics Inc.

Oragenics Q3 2025 Shareholder Update
Oragenics Regains Full NYSE American Compliance, Company Resolves Stockholder Equity Deficiency
Oragenics Announces Strategic Partnership with Receptor.AI to Accelerate Pipeline Development
Oragenics Q2 2025 Shareholder Update
Oragenics Selects Southern Star Research as Clinical Research Organization for ONP-002 Phase IIa Trial
Oragenics, Inc. Announces U.S.-Based Drug Manufacturing Agreement to Support ONP-002 Clinical Development
Oragenics Completes Approximately $16.5 Million Offering
Oragenics, Inc. Announces Pricing of Public Offering of up to $20 Million of Preferred Stock and Warrants

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.